Roth Capital Pounds Table on Jounce Therapeutics (JNCE)

Roth Capital analyst Zegbah Ja;;ah reiterated a Buy rating and $20.00 price target on Jounce Therapeutics (NASDAQ: JNCE).

The analyst comments "Jounce recently reported 1Q2022 corporate and financial updates. Of continued focus for 2H2022 are 1) Phase 1/2 data from the INNATE study of JTX-8064 (LILRB2) monotherapy, and in combo with Pimivalimab (PD-1) in solid tumors, and 2) Phase 2 data from the SELECT study of Vopra (ICOS) + Pimivalimab (PD-1) vs. Pimi alone in NSCLC. With two key readouts, a strong discovery engine, and cash runway into 3Q2023 (excluding milestone payments from Gilead (GILD-NC)), we are reiterating our Buy rating."

For an analyst ratings summary and ratings history on Jounce Therapeutics click here. For more ratings news on Jounce Therapeutics click here.

Shares of Jounce Therapeutics closed at $4.29 yesterday.

You May Also Be Interested In